Inflammatory bowel disease (IBD) is an ongoing or chronic health problem that causes inflammation and swelling in the digestive tract. The irritation causes bleeding sores called ulcers to form along the digestive tract. This in turn can cause crampy, abdominal pain and severe bloody diarrhea.
There are two main types of inflammatory bowel disease: ulcerative colitis (UC) and Crohn's disease (CD). The diseases are very similar. In fact, doctors often have a hard time figuring out which type of IBD a person has. The main difference between UC and CD is the area of the digestive tract they affect. CD can occur along the entire digestive tract and spread deep into the bowel wall. In contrast, UC usually only affects the top layer of the large intestine (colon) and rectum. Medicine can control the symptoms of IBD in most women. But for people who have severe IBD, surgery is sometimes needed. Over the course of a person's life, the symptoms of IBD often come and go. With close monitoring and medicines, most people with IBD lead full and active lives.
New research indicates that the incidence of inflammatory bowel disease-including ulcerative colitis (UC) and Crohn's disease (CD)-in Denmark is on the rise and is among the highest in the world.
Institute scientists have revealed a potent inflammatory molecule released by dying cells triggers inflammation during necroptosis, a recently described form of cell death linked to inflammatory disease.
The 12th ECCO Congress that took place in Barcelona, Spain, from 15 to 18 February 2017, was an excellent opportunity for Vifor Pharma to continue its support of healthcare efforts and to highlight the detrimental impact of iron deficiency, a particularly common condition in people with certain chronic diseases such as inflammatory bowel disease (IBD).
A new study led by researchers at Beth Israel Deaconess Medical Center has found that lower levels of vitamin D in the blood increase the risk of clinical relapse in patients with Ulcerative Colitis, an inflammatory bowel disease that causes long-lasting inflammation and ulcers in the colon.
New research shows that nearly three-quarters of patients with moderate to severe ulcerative colitis (UC) taking conventional treatments describe their disease as ‘poorly controlled’ (continuous or regular experience of symptoms that negatively affect quality of life), with half saying they are somewhat or completely dissatisfied with their current medication; only 1% were completely satisfied with their current treatment.
The discovery of the 'molecular switch' that causes inflammatory bowel disease (IBD) and Celiac disease, could lead to more effective new treatments for these life-changing auto-immune conditions, according to research from scientists at King's College London and University College London.
The human gut is home to some 100 trillion bacteria, comprising between 250 and 500 species. This astounding array of organisms, collectively known as the gut microbiome, is a powerful regulator of disease and health and has been implicated in conditions ranging from inflammatory bowel disease to multiple sclerosis.
Patients with inflammatory bowel disease are more likely to see dramatic shifts in the make-up of the community of microbes in their gut than healthy people, according to the results of a study published online Feb. 13 in Nature Microbiology.
Patients with Crohn's disease, a type of inflammatory bowel disease (IBD) that causes abdominal pain and diarrhea, can also experience joint pain.
A study led by UT Southwestern Medical Center researchers has uncovered key molecular pathways behind the disruption of the gut's delicate balance of bacteria during episodes of inflammatory disease.
As a society, we may be more obsessed with food than we've ever been. The alarming levels of obesity along with the rise of clean eating and orthorexia are perhaps just some indicators of the food-obsessed world we live in.
UT Southwestern Medical Center researchers have identified a gene that protects the gut from inflammatory bowel disease.
Could inflammatory bowel disease and colon cancer be prevented by changing the shape of a single protein?There is an intimate link between uncontrolled inflammation in the gut associated with inflammatory bowel disease and the eventual development of colon cancer.
A growing body of evidence indicates that the trillions of microbes that live on and inside our bodies affect our health. Collectively, these resident microbes form our microbiome.
Researchers from Schepens Eye Research Institute of Massachusetts Eye and Ear have uncovered two factors responsible for the chronic, lifelong nature of autoimmune disorders, which tend to "flare up" intermittently in affected patients.
Researchers have developed the first sensor capable of objectively identifying inflammatory bowel disease (IBD) and distinguishing between its two subtypes.
An enzyme that plays an active role in inflammation could be a natural way to suppress tumors and ulcers in the colon that are found in colitis associated cancer (CAC), a type of colorectal cancer that is driven by chronic inflammation, according to a new study.
A more powerful version of an anti-inflammatory molecule already circulating in our blood may help protect our vision in the face of diabetes.
In a first-of-its-kind study published today in the Journal of Clinical Gastroenterology, researchers from Seattle Children's and Children's Healthcare of Atlanta, led by Dr. David Suskind, a Seattle Children's gastroenterologist, found that diet alone can bring pediatric patients with active Crohn's disease and ulcerative colitis (UC) into clinical remission.
Researchers have found evidence that could shed new light on the complex community of trillions of microorganisms living in all our guts, and how they interact with our bodies.